Race Oncology Ltd has released a press release.
Bisantrene IND Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race files Bisantrene IND with FDA
- Principal Investigator appointed for Bisantrene
- Race Receives $228k R&D Tax Incentive Refund
- Race appoints leading haematologist to support Bisantrene
- Race signs agreement for Bisantrene NPP in Israel
Later from Racura Oncology
- Bisantrene AML trial to start in Israel
- First patient treated in Bisantrene trial in Israel
- Prominent biotech investor leads investment in Race
- Appendix 4C - quarterly
- Race reveals new strategy for cancer drug Bisantrene
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology